Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VVN539 Ophthalmic Solution is a first-in-class small molecule for the treatment of glaucoma. It acts directly at trabecular meshwork, increases the outflow of aqueous humor for the treatment of with primary open angle glaucoma.
Lead Product(s): VVN539
Therapeutic Area: Ophthalmology Product Name: VVN539
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2023
Details:
Under the terms of collaboration agreement, VivaVision and Everads will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everads Therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2023